Navigation Links
Mylan Launches Generic Version of Wellbutrin XL® Tablets
Date:10/1/2010

PITTSBURGH, Oct. 1 /PRNewswire/ -- Mylan Inc. (Nasdaq: MYL) today announced that its subsidiary Mylan Pharmaceuticals Inc. has launched Bupropion Hydrochloride Extended-release Tablets USP, (XL), 150 mg and 300 mg (Once-Daily), the generic version of GlaxoSmithKline's antidepressant Wellbutrin XL®.

Bupropion Hydrochloride Extended-release Tablets had U.S. sales of approximately $752 million for the 12 months ending June 30, 2010, according to IMS Health.

Currently, Mylan has 150 ANDAs pending FDA approval representing $94.2 billion in annual sales, according to IMS Health. Forty-two of these pending ANDAs are potential first-to-file opportunities, representing $21.9 billion in annual brand sales, for the 12 months ending June 30, 2010, according to IMS Health.

Mylan Inc. ranks among the leading generic and specialty pharmaceutical companies in the world and provides products to customers in more than 140 countries and territories. The company maintains one of the industry's broadest and highest quality product portfolios supported by a robust product pipeline; operates one of the world's largest active pharmaceutical ingredient manufacturers; and runs a specialty business focused on respiratory, allergy and psychiatric therapies. For more information, please visit www.mylan.com.


'/>"/>
SOURCE Mylan Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1

Related medicine technology :

1. Mylan Granted Temporary Restraining Order Against GlaxoSmithKline and Apotex Prohibiting the Supply, Sale and/or Importing of a Generic Version of Paxil CR
2. Mylan Receives Approval for Generic Version of Prograf® Capsules
3. Mylan Completes Acquisition of Bioniche Pharma Sooner Than Expected
4. Mylan Announces Completion of Add-On Offering of Senior Notes
5. Mylan Announces Pricing of Add-On Offering of Senior Notes
6. Mylan Launches the Generic Version of Solodyn®, 45 mg, 90 mg and 135 mg Tablets, Announces Settlement Agreement with Medicis
7. Mylan Announces Settlement Agreement for Namenda®
8. Mylan to Acquire Bioniche Pharma Global Injectable Pharmaceuticals Business
9. RoundTable Healthcare Partners Announces Sale of Bioniche Pharma Holdings Limited to Mylan Inc.
10. Mylan Receives Approval for Nabumetone Tablets
11. Mylan Schedules Second Quarter 2010 Financial Results Conference Call and Live Webcast
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/4/2016)... DUBLIN , May 4, 2016 /PRNewswire/ ... the addition of the  "Global Multiple Myeloma ...  report to their offering.       ... Multiple Myeloma Market and Competitive Landscape Highlights ... pipeline products, Multiple Myeloma epidemiology, Multiple Myeloma ...
(Date:5/4/2016)... Research and Markets has ... Keratosis Market and Competitive Landscape Highlights - ...      (Logo: http://photos.prnewswire.com/prnh/20160330/349511LOGO ) , ... Highlights 2016, provides comprehensive insights into Actinic ... Keratosis market valuations and forecast, Actinic Keratosis ...
(Date:5/3/2016)... May 3, 2016 BioNovus Innovations LLC ... for Advancing Medical Innovation (IAMI) today announced a ... diagnostics and medical devices. An agreement ... rights to license, develop and commercialize medical innovations ... "This partnership represents a significant advance in ...
Breaking Medicine Technology:
(Date:5/4/2016)... ... May 04, 2016 , ... ... new patent for its innovative Secure Messaging platform, which includes secure, private messaging, ... new patent extends Cirius’s portfolio of patents around innovative features for securing, tracking, ...
(Date:5/4/2016)... (PRWEB) , ... May 04, 2016 , ... ... sleep wellness and sleep disorder management, today announced it has secured $9 million ... Lab (WiL) and existing investors. The investment will be used by Somnoware to ...
(Date:5/4/2016)... , ... May 04, 2016 , ... ... products, announced today the introduction of the innovative newly improved Iso-Hip Wrap. ... replacement patients. The plush design enhances comfort and enables the patient to enjoy ...
(Date:5/4/2016)... ... May 04, 2016 , ... a2z, Inc. is pleased ... Canadian Association for Enterostomal Therapy (CAET) will be utilizing powerful and innovative technology ... attendees and exhibitors for the 2016 WOCN Society & CAET Joint Conference—which is ...
(Date:5/4/2016)... ... May 04, 2016 , ... Washington Wellness Center today announced ... New Jersey residents. What started out as an idea to provide a holistic ... approach to healthcare. , Developed by Dr. David Swanekamp, Chiropractic Physician , the ...
Breaking Medicine News(10 mins):